-
1
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-34.
-
(2003)
N Engl J Med
, vol.349
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
Hwu, P.4
Schwartzentruber, D.J.5
Topalian, S.L.6
-
2
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
-
3
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
-
4
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-76.
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
Dickler, M.4
Cobleigh, M.5
Perez, E.A.6
-
5
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
-
6
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, M.D.4
Bukowski, R.M.5
Rixe, O.6
-
7
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
-
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-11.
-
(2007)
Lancet
, vol.370
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
-
8
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
-
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-8.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
Szczylik, C.4
Lee, E.5
Wagstaff, J.6
-
9
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-81.
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
Dutcher, J.4
Figlin, R.5
Kapoor, A.6
-
10
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
-
11
-
-
82755183572
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
-
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-9.
-
(2011)
Lancet
, vol.378
, pp. 1931-1939
-
-
Rini, B.I.1
Escudier, B.2
Tomczak, P.3
Kaprin, A.4
Szczylik, C.5
Hutson, T.E.6
-
12
-
-
84991063392
-
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
-
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917-27.
-
(2016)
Lancet Oncol
, vol.17
, pp. 917-927
-
-
Choueiri, T.K.1
Escudier, B.2
Powles, T.3
Tannir, N.M.4
Mainwaring, P.N.5
Rini, B.I.6
-
13
-
-
84955253186
-
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
-
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473-82.
-
(2015)
Lancet Oncol
, vol.16
, pp. 1473-1482
-
-
Motzer, R.J.1
Hutson, T.E.2
Glen, H.3
Michaelson, M.D.4
Molina, A.5
Eisen, T.6
-
14
-
-
49249113484
-
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
-
Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26:3709-14.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3709-3714
-
-
Azad, N.S.1
Posadas, E.M.2
Kwitkowski, V.E.3
Steinberg, S.M.4
Jain, L.5
Annunziata, C.M.6
-
15
-
-
79959549917
-
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
-
Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay JO, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12:673-80.
-
(2011)
Lancet Oncol
, vol.12
, pp. 673-680
-
-
Negrier, S.1
Gravis, G.2
Perol, D.3
Chevreau, C.4
Delva, R.5
Bay, J.O.6
-
16
-
-
84888009143
-
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine tumour group (GETNE0801)
-
Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, Garcia-Carbonero R, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine tumour group (GETNE0801). Eur J Cancer. 2013;49:3780-7.
-
(2013)
Eur J Cancer
, vol.49
, pp. 3780-3787
-
-
Castellano, D.1
Capdevila, J.2
Sastre, J.3
Alonso, V.4
Llanos, M.5
Garcia-Carbonero, R.6
-
17
-
-
84884818834
-
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier oncology group study BRE06-109
-
Mina LA, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier oncology group study BRE06-109. Investig New Drugs. 2013;31:1307-10.
-
(2013)
Investig New Drugs
, vol.31
, pp. 1307-1310
-
-
Mina, L.A.1
Yu, M.2
Johnson, C.3
Burkhardt, C.4
Miller, K.D.5
Zon, R.6
-
18
-
-
84903818179
-
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma
-
Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, et al. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2014;74:77-84.
-
(2014)
Cancer Chemother Pharmacol
, vol.74
, pp. 77-84
-
-
Mahalingam, D.1
Malik, L.2
Beeram, M.3
Rodon, J.4
Sankhala, K.5
Mita, A.6
-
19
-
-
84883474833
-
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial
-
Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res. 2013;19:4816-23.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4816-4823
-
-
Galanis, E.1
Anderson, S.K.2
Lafky, J.M.3
Uhm, J.H.4
Giannini, C.5
Kumar, S.K.6
-
20
-
-
84960955915
-
Combination therapy in kidney cancer: the next revolution?
-
Buti S, Bersanelli M. Combination therapy in kidney cancer: the next revolution? Lancet Oncol. 2015;16:1441-2.
-
(2015)
Lancet Oncol
, vol.16
, pp. 1441-1442
-
-
Buti, S.1
Bersanelli, M.2
-
21
-
-
84874095390
-
Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab
-
Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res. 2013;19:929-37.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 929-937
-
-
Hegde, P.S.1
Jubb, A.M.2
Chen, D.3
Li, N.F.4
Meng, Y.G.5
Bernaards, C.6
-
22
-
-
0242653716
-
Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma
-
Ljungberg B, Jacobsen J, Haggstrom-Rudolfssson S, Rasmuson T, Lindh G, Grankvist K. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res. 2003;31:335-40.
-
(2003)
Urol Res
, vol.31
, pp. 335-340
-
-
Ljungberg, B.1
Jacobsen, J.2
Haggstrom-Rudolfssson, S.3
Rasmuson, T.4
Lindh, G.5
Grankvist, K.6
-
23
-
-
2942756034
-
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie
-
Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol. 2004;22:2371-8.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2371-2378
-
-
Negrier, S.1
Perol, D.2
Menetrier-Caux, C.3
Escudier, B.4
Pallardy, M.5
Ravaud, A.6
-
24
-
-
85010936479
-
Systemic therapy for metastatic renal-cell carcinoma
-
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354-66.
-
(2017)
N Engl J Med
, vol.376
, pp. 354-366
-
-
Choueiri, T.K.1
Motzer, R.J.2
-
25
-
-
63049093371
-
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma
-
Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432-9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1432-1439
-
-
Feldman, D.R.1
Baum, M.S.2
Ginsberg, M.S.3
Hassoun, H.4
Flombaum, C.D.5
Velasco, S.6
-
26
-
-
70349673595
-
A phase I study of sunitinib plus bevacizumab in advanced solid tumors
-
Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res. 2009;15:6277-83.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 6277-6283
-
-
Rini, B.I.1
Garcia, J.A.2
Cooney, M.M.3
Elson, P.4
Tyler, A.5
Beatty, K.6
-
27
-
-
84863888220
-
V, Basu B, Molife LR, Kaye SB: combining antiangiogenics to overcome resistance: rationale and clinical experience
-
Moreno G. V, Basu B, Molife LR, Kaye SB: combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res. 2012;18:3750-61.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3750-3761
-
-
Moreno, G.1
-
28
-
-
84905510166
-
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers
-
Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, et al. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer Biol Ther. 2014;15:975-81.
-
(2014)
Cancer Biol Ther
, vol.15
, pp. 975-981
-
-
Mittal, K.1
Koon, H.2
Elson, P.3
Triozzi, P.4
Dowlati, A.5
Chen, H.6
-
29
-
-
75749090050
-
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma
-
Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28:475-80.
-
(2010)
J Clin Oncol
, vol.28
, pp. 475-480
-
-
Hutson, T.E.1
Davis, I.D.2
Machiels, J.P.3
De Souza, P.L.4
Rottey, S.5
Hong, B.F.6
-
30
-
-
56749161699
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
-
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422-8.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5422-5428
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
Stadler, W.M.4
Vaena, D.A.5
Ou, S.S.6
-
31
-
-
35648938219
-
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
-
Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25:4536-41.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4536-4541
-
-
Bukowski, R.M.1
Kabbinavar, F.F.2
Figlin, R.A.3
Flaherty, K.4
Srinivas, S.5
Vaishampayan, U.6
-
32
-
-
84940394410
-
BEST: a randomized phase II study of vascular endothelial growth factor, RAF Kinase, and mammalian target of Rapamycin combination targeted therapy with Bevacizumab, Sorafenib, and Temsirolimus in advanced renal cell carcinoma--a trial of the ECOG-ACRIN cancer research group (E2804)
-
Flaherty KT, Manola JB, Pins M, McDermott DF, Atkins MB, Dutcher JJ, et al. BEST: a randomized phase II study of vascular endothelial growth factor, RAF Kinase, and mammalian target of Rapamycin combination targeted therapy with Bevacizumab, Sorafenib, and Temsirolimus in advanced renal cell carcinoma--a trial of the ECOG-ACRIN cancer research group (E2804). J Clin Oncol. 2015;33:2384-91.
-
(2015)
J Clin Oncol
, vol.33
, pp. 2384-2391
-
-
Flaherty, K.T.1
Manola, J.B.2
Pins, M.3
McDermott, D.F.4
Atkins, M.B.5
Dutcher, J.J.6
-
33
-
-
2942657615
-
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
-
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-91.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2184-2191
-
-
Johnson, D.H.1
Fehrenbacher, L.2
Novotny, W.F.3
Herbst, R.S.4
Nemunaitis, J.J.5
Jablons, D.M.6
-
34
-
-
77649322923
-
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer
-
Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol. 2010;5:354-60.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 354-360
-
-
Socinski, M.A.1
Scappaticci, F.A.2
Samant, M.3
Kolb, M.M.4
Kozloff, M.F.5
-
35
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
36
-
-
84903814883
-
Pharmacokinetics of pazopanib administered in combination with bevacizumab
-
Imbs DC, Negrier S, Cassier P, Hollebecque A, Varga A, Blanc E, et al. Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemother Pharmacol. 2014;73:1189-96.
-
(2014)
Cancer Chemother Pharmacol
, vol.73
, pp. 1189-1196
-
-
Imbs, D.C.1
Negrier, S.2
Cassier, P.3
Hollebecque, A.4
Varga, A.5
Blanc, E.6
-
37
-
-
67449164582
-
Phase I trial of pazopanib in patients with advanced cancer
-
Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15:4220-7.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4220-4227
-
-
Hurwitz, H.I.1
Dowlati, A.2
Saini, S.3
Savage, S.4
Suttle, A.B.5
Gibson, D.M.6
-
38
-
-
84882781441
-
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-31.
-
(2013)
N Engl J Med
, vol.369
, pp. 722-731
-
-
Motzer, R.J.1
Hutson, T.E.2
Cella, D.3
Reeves, J.4
Hawkins, R.5
Guo, J.6
-
39
-
-
84902986833
-
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study
-
Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32:1412-8.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1412-1418
-
-
Escudier, B.1
Porta, C.2
Bono, P.3
Powles, T.4
Eisen, T.5
Sternberg, C.N.6
-
40
-
-
84861098484
-
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
-
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879-86.
-
(2012)
Lancet
, vol.379
, pp. 1879-1886
-
-
van der Graaf, W.T.1
Blay, J.Y.2
Chawla, S.P.3
Kim, D.W.4
Bui-Nguyen, B.5
Casali, P.G.6
-
41
-
-
84880278381
-
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients
-
Kapadia S, Hapani S, Choueiri TK, Wu S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol. 2013;52:1202-12.
-
(2013)
Acta Oncol
, vol.52
, pp. 1202-1212
-
-
Kapadia, S.1
Hapani, S.2
Choueiri, T.K.3
Wu, S.4
-
42
-
-
33846484966
-
Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma
-
Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol. 2007;8:177-8.
-
(2007)
Lancet Oncol
, vol.8
, pp. 177-178
-
-
Frangie, C.1
Lefaucheur, C.2
Medioni, J.3
Jacquot, C.4
Hill, G.S.5
Nochy, D.6
-
43
-
-
40849130173
-
VEGF inhibition and renal thrombotic microangiopathy
-
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-36.
-
(2008)
N Engl J Med
, vol.358
, pp. 1129-1136
-
-
Eremina, V.1
Jefferson, J.A.2
Kowalewska, J.3
Hochster, H.4
Haas, M.5
Weisstuch, J.6
-
44
-
-
34848922067
-
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
-
Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007;18:1745-7.
-
(2007)
Ann Oncol
, vol.18
, pp. 1745-1747
-
-
Kapiteijn, E.1
Brand, A.2
Kroep, J.3
Gelderblom, H.4
-
45
-
-
84896042886
-
A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies
-
Bruce JY, Kolesar JM, Hammers H, Stein MN, Carmichael L, Eickhoff J, et al. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies. Cancer Chemother Pharmacol. 2014;73:485-93.
-
(2014)
Cancer Chemother Pharmacol
, vol.73
, pp. 485-493
-
-
Bruce, J.Y.1
Kolesar, J.M.2
Hammers, H.3
Stein, M.N.4
Carmichael, L.5
Eickhoff, J.6
-
46
-
-
84894207820
-
Improved survival with bevacizumab in advanced cervical cancer
-
Tewari KS, Sill MW, Long HJ III, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734-43.
-
(2014)
N Engl J Med
, vol.370
, pp. 734-743
-
-
Tewari, K.S.1
Sill, M.W.2
Long, H.J.3
Penson, R.T.4
Huang, H.5
Ramondetta, L.M.6
|